Pentwater Capital Management Reduces $67M in Atrium Therapeutics, Inc. ($RNA)
Key Points
- Pentwater Capital Management changed its Atrium Therapeutics, Inc. ($RNA) stake by 90.0% last quarter, cutting to 602,649 shares worth $7.45 million.
- $RNA last traded around $12.37.
Pentwater Capital Management reduced its position in Atrium Therapeutics, Inc. ($RNA) by 90.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 602,649 shares of Atrium Therapeutics, Inc. after selling 5,423,851 shares during the quarter. Pentwater Capital Management's holdings in Atrium Therapeutics, Inc. were worth $7.45 million as of its most recent filing.
Atrium Therapeutics, Inc. ($RNA) Stock
Atrium Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.